Symbols / MRKR Stock $1.41 -3.42% Marker Therapeutics, Inc.

Healthcare • Biotechnology • United States • NCM
MRKR (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Juan F. Vera M.D.
Exch · Country NCM · United States
Market Cap 23.51M
Enterprise Value 8.59M
Income -10.90M
Sales 3.55M
FCF (ttm) -5.25M
Book/sh 0.83
Cash/sh 0.90
Employees 5
Insider 10d —
IPO Jul 16, 2002
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -8.29
PEG —
P/S 6.63
P/B 1.70
P/C —
EV/EBITDA —
EV/Sales 2.42
Quick Ratio 4.48
Current Ratio 4.79
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -0.55
EPS next Y -0.17
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-15
Earnings (prior) 2026-05-15
ROA -43.59%
ROE -77.04%
ROIC —
Gross Margin -224.43%
Oper. Margin -3.38%
Profit Margin 0.00%
Shs Outstand 16.67M
Shs Float 13.81M
Insider Own 5.49%
Instit Own 23.40%
Short Float 1.51%
Short Ratio 3.21
Short Interest 204.42K
52W High 4.07
vs 52W High -65.36%
52W Low 0.81
vs 52W Low 74.07%
Beta 1.45
Impl. Vol. —
Rel Volume 0.26
Avg Volume 103.76K
Volume 27.30K
Target (mean) $7.87
Tgt Median $8.00
Tgt Low $5.60
Tgt High $10.00
# Analysts 3
Recom None
Prev Close $1.46
Price $1.41
Change -3.42%
About

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreatic cancer; and MT-401-OTS, which is in a Phase 1 trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company was formerly known as TapImmune, Inc. and changed its name to Marker Therapeutics, Inc. in October 2018. Marker Therapeutics, Inc. was founded in 1999 and is headquartered in Houston, Texas.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$7.87
Mean price target
2. Current target
$1.41
Latest analyst target
3. DCF / Fair value
$-5.67
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.41
Low
$5.60
High
$10.00
Mean
$7.87

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-12-08 init HC Wainwright & Co. — → Buy $10
2025-04-01 reit WBB Securities Strong Buy → Strong Buy $13
2025-03-05 init Canaccord Genuity — → Buy $8
2024-04-30 init Ladenburg Thalmann — → Buy $11
News
RSS: Latest MRKR news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2024-12-23 ELMS STEVEN A Director — 11,085 $3.20 $35,472
2024-12-23 NEW ENTERPRISE ASSOCIATES 16, L.P. Beneficial Owner of more than 10% of a Class of Security — 554,250 $3.20 $1,773,600
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
-100.00%
3.31
0.00
Operating Revenue
0.00
0.00
-100.00%
3.31
0.00
Operating Expense
12.44
+11.86%
11.12
-23.75%
14.58
-26.32%
19.79
Research And Development
11.80
-12.39%
13.47
+29.29%
10.42
-12.96%
11.97
Selling General And Administration
4.18
-1.34%
4.24
-43.26%
7.48
-34.05%
11.34
General And Administrative Expense
4.18
-1.34%
4.24
-43.26%
7.48
-34.05%
11.34
Other Gand A
4.18
-1.34%
4.24
-43.26%
7.48
-34.05%
11.34
Other Operating Expenses
-3.55
+46.19%
-6.59
-99.06%
-3.31
+5.76%
-3.51
Total Expenses
12.44
+11.86%
11.12
-23.75%
14.58
-26.32%
19.79
Operating Income
-12.44
-11.86%
-11.12
+1.35%
-11.27
+43.05%
-19.79
Total Operating Income As Reported
-12.89
-15.94%
-11.12
+23.75%
-14.58
+26.32%
-19.79
EBITDA
-12.44
-11.86%
-11.12
+1.35%
-11.27
+43.05%
-19.79
Normalized EBITDA
-11.98
-7.79%
-11.12
+1.35%
-11.27
+43.05%
-19.79
Reconciled Depreciation
—
—
—
3.68
EBIT
-12.44
-11.86%
-11.12
+1.35%
-11.27
+43.05%
-19.79
Total Unusual Items
-0.45
0.00
—
—
Total Unusual Items Excluding Goodwill
-0.45
0.00
—
—
Special Income Charges
-0.45
0.00
—
—
Other Special Charges
0.45
—
—
—
Net Income
-12.16
-13.35%
-10.73
-30.28%
-8.24
+72.48%
-29.93
Pretax Income
-12.18
-14.02%
-10.68
+0.46%
-10.73
+45.74%
-19.78
Net Non Operating Interest Income Expense
0.59
+35.97%
0.44
-18.95%
0.54
+117.35%
0.25
Net Interest Income
0.59
+35.97%
0.44
-18.95%
0.54
+117.35%
0.25
Interest Income Non Operating
0.59
+35.97%
0.44
-18.95%
0.54
+117.35%
0.25
Interest Income
0.59
+35.97%
0.44
-18.95%
0.54
+117.35%
0.25
Other Income Expense
-0.34
—
—
-0.23
Other Non Operating Income Expenses
0.12
—
—
-0.23
Tax Provision
-0.02
-130.34%
0.05
+1259.27%
0.00
0.00
Tax Rate For Calcs
0.00
-100.00%
0.00
+0.00%
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-12.16
-13.35%
-10.73
-30.28%
-8.24
+72.48%
-29.93
Net Income From Continuing Operation Net Minority Interest
-12.16
-13.35%
-10.73
+23.60%
-14.05
+28.97%
-19.78
Net Income From Continuing And Discontinued Operation
-12.16
-13.35%
-10.73
-30.28%
-8.24
+72.48%
-29.93
Net Income Continuous Operations
-12.16
-13.35%
-10.73
+23.60%
-14.05
+28.97%
-19.78
Net Income Discontinuous Operations
—
0.00
-100.00%
5.81
+157.21%
-10.15
Normalized Income
-11.71
-9.12%
-10.73
+23.60%
-14.05
+28.97%
-19.78
Net Income Common Stockholders
-12.16
-13.35%
-10.73
-30.28%
-8.24
+72.48%
-29.93
Diluted EPS
-0.79
+33.61%
-1.19
-26.60%
-0.94
+73.74%
-3.58
Basic EPS
-0.79
+33.61%
-1.19
-26.60%
-0.94
+73.74%
-3.58
Basic Average Shares
15.31
+70.49%
8.98
+1.94%
8.81
+5.49%
8.35
Diluted Average Shares
15.31
+70.49%
8.98
+1.94%
8.81
+5.49%
8.35
Diluted NI Availto Com Stockholders
-12.16
-13.35%
-10.73
-30.28%
-8.24
+72.48%
-29.93
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
19.07
-13.40%
22.02
+28.58%
17.13
-50.24%
34.42
Current Assets
19.07
-13.40%
22.02
+28.58%
17.13
+3.06%
16.62
Cash Cash Equivalents And Short Term Investments
16.07
-16.28%
19.19
+27.01%
15.11
+28.26%
11.78
Cash And Cash Equivalents
16.07
-16.28%
19.19
+27.01%
15.11
+28.26%
11.78
Receivables
1.37
-41.65%
2.35
+128.32%
1.03
-57.21%
2.40
Other Receivables
1.37
-41.65%
2.35
+128.32%
1.03
-57.21%
2.40
Prepaid Assets
0.66
+36.19%
0.48
-51.05%
0.99
-46.57%
1.85
Restricted Cash
0.97
0.00
—
0.00
Assets Held For Sale Current
—
—
0.00
-100.00%
0.59
Total Non Current Assets
0.00
0.00
0.00
-100.00%
17.80
Net PPE
—
—
—
17.80
Gross PPE
—
—
—
23.08
Accumulated Depreciation
—
—
—
-5.27
Properties
—
—
—
0.00
Machinery Furniture Equipment
—
—
—
1.82
Construction In Progress
—
—
—
0.00
Other Properties
—
—
—
17.30
Leases
—
—
—
3.95
Other Non Current Assets
—
—
—
17.80
Total Liabilities Net Minority Interest
2.27
-34.36%
3.46
+12.67%
3.07
-79.25%
14.82
Current Liabilities
2.27
-34.36%
3.46
+12.67%
3.07
-60.49%
7.78
Payables And Accrued Expenses
1.21
-64.11%
3.38
+11.94%
3.02
+70.39%
1.77
Payables
0.85
-70.56%
2.88
+14.82%
2.51
+127.94%
1.10
Accounts Payable
0.79
-25.57%
1.07
+10.97%
0.96
-12.72%
1.10
Current Accrued Expenses
0.36
-26.72%
0.50
-2.24%
0.51
-24.18%
0.67
Pensionand Other Post Retirement Benefit Plans Current
0.09
+0.85%
0.09
+51.49%
0.06
-92.40%
0.75
Total Tax Payable
0.05
-47.76%
0.10
-52.24%
0.22
0.00
Current Debt And Capital Lease Obligation
—
—
—
0.58
Current Capital Lease Obligation
—
—
—
0.58
Current Deferred Liabilities
0.97
0.00
—
2.50
Current Deferred Revenue
0.97
0.00
—
2.50
Other Current Liabilities
—
0.00
+394.30%
0.00
-100.00%
5.26
Total Non Current Liabilities Net Minority Interest
0.00
0.00
0.00
-100.00%
7.04
Liabilities Heldfor Sale Non Current
—
—
0.00
-100.00%
7.04
Long Term Debt And Capital Lease Obligation
—
—
—
7.04
Long Term Capital Lease Obligation
—
—
—
7.04
Stockholders Equity
16.80
-9.49%
18.56
+32.06%
14.05
-28.31%
19.60
Common Stock Equity
16.80
-9.49%
18.56
+32.06%
14.05
-28.31%
19.60
Capital Stock
0.02
+55.70%
0.01
+20.44%
0.01
+5.77%
0.01
Common Stock
0.02
+55.70%
0.01
+20.44%
0.01
+5.77%
0.01
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
16.67
+55.69%
10.71
+20.33%
8.90
+5.95%
8.40
Ordinary Shares Number
16.67
+55.69%
10.71
+20.33%
8.90
+5.95%
8.40
Additional Paid In Capital
475.96
+2.23%
465.56
+3.38%
450.33
+0.60%
447.64
Retained Earnings
-459.18
-2.72%
-447.02
-2.46%
-436.29
-1.92%
-428.05
Total Equity Gross Minority Interest
16.80
-9.49%
18.56
+32.06%
14.05
-28.31%
19.60
Total Capitalization
16.80
-9.49%
18.56
+32.06%
14.05
-28.31%
19.60
Working Capital
16.80
-9.49%
18.56
+32.06%
14.05
+59.01%
8.84
Invested Capital
16.80
-9.49%
18.56
+32.06%
14.05
-28.31%
19.60
Total Debt
—
—
—
7.62
Capital Lease Obligations
—
—
—
7.62
Net Tangible Assets
16.80
-9.49%
18.56
+32.06%
14.05
-28.31%
19.60
Tangible Book Value
16.80
-9.49%
18.56
+32.06%
14.05
-28.31%
19.60
Dueto Related Parties Current
0.00
-100.00%
1.71
+28.64%
1.33
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-12.01
-10.12%
-10.91
+33.64%
-16.44
+39.05%
-26.97
Cash Flow From Continuing Operating Activities
-12.01
-10.12%
-10.91
-5.50%
-10.34
+51.93%
-21.51
Cash From Discontinued Operating Activities
—
0.00
+100.00%
-6.10
-11.73%
-5.46
Net Income From Continuing Operations
-12.16
-13.35%
-10.73
+23.60%
-14.05
+28.97%
-19.78
Depreciation Amortization Depletion
—
—
—
3.68
Depreciation
—
—
—
3.68
Depreciation And Amortization
—
—
—
3.68
Other Non Cash Items
—
—
—
-0.28
Stock Based Compensation
0.54
+118.63%
0.25
-71.35%
0.86
-74.03%
3.30
Operating Gains Losses
—
—
—
0.03
Gain Loss On Sale Of PPE
—
—
—
0.03
Change In Working Capital
-0.39
+8.68%
-0.42
-114.93%
2.85
+159.76%
-4.76
Change In Receivables
0.98
+174.10%
-1.32
-195.98%
1.37
+157.22%
-2.40
Change In Prepaid Assets
-0.18
-134.70%
0.50
-41.42%
0.86
+726.82%
0.10
Change In Payables And Accrued Expense
-2.17
-655.71%
0.39
-36.26%
0.61
+146.32%
-1.32
Change In Payable
-2.17
-655.71%
0.39
-36.26%
0.61
—
Change In Account Payable
-0.45
-5288.56%
0.01
+101.22%
-0.72
—
Change In Other Working Capital
0.97
—
—
-1.15
Change In Other Current Liabilities
—
—
—
-0.51
Investing Cash Flow
—
0.00
-100.00%
18.66
+477.42%
-4.95
Cash Flow From Continuing Investing Activities
—
—
—
-4.95
Cash From Discontinued Investing Activities
—
0.00
-100.00%
18.66
+477.42%
-4.95
Net PPE Purchase And Sale
—
—
—
-4.95
Purchase Of PPE
—
—
—
-4.95
Capital Expenditure
—
—
—
-4.95
Financing Cash Flow
9.86
-34.20%
14.99
+1256.54%
1.11
+446.74%
0.20
Cash Flow From Continuing Financing Activities
9.86
-34.20%
14.99
+1256.54%
1.11
+446.74%
0.20
Net Common Stock Issuance
9.86
-33.93%
14.93
+1371.37%
1.01
+401.97%
0.20
Proceeds From Stock Option Exercised
0.00
-99.03%
0.06
-31.30%
0.09
0.00
Changes In Cash
-2.15
-152.67%
4.08
+22.58%
3.33
+110.50%
-31.72
Beginning Cash Position
19.19
+27.01%
15.11
+28.26%
11.78
-72.91%
43.50
End Cash Position
17.04
-11.20%
19.19
+27.01%
15.11
+28.26%
11.78
Free Cash Flow
-12.01
-10.12%
-10.91
+33.64%
-16.44
+39.05%
-26.97
Common Stock Issuance
9.86
-33.93%
14.93
+1371.37%
1.01
+401.97%
0.20
Issuance Of Capital Stock
9.86
-33.93%
14.93
+1371.37%
1.01
+401.97%
0.20
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category